Citing a lack of incubator lab space in the Triad, Kucera Pharmaceutical Company has transferred its chemical synthesis lab to RTP.

Kucera, a spinout of Wake Forest University and UNC Chapel Hill that started operations in 2001, said the lab and several employees would be relocated to the North Carolina Technological Development Authority’s LifeScience Center in RTP.

Dave Emmett, head of the NCTDA, said four to five employees would utilize the space.

In a statement, Dr. Ronald Fleming said Kucera chose the NCTDA because of the facilities that are available.

“The LifeScience Center offers top-notch, sate-of-the-art laboratory facilities that will enable us to do our work most effectively,” said Fleming, who is Kucera’s chief scientific officer.

The center has more than 20,000 square feet of flexible office and lab space. It has backup power generation, card access security, and other features.

Kucera’s headquarters will remain in the Piedmont Triad Research Park.

The company currently is researching a new chemical molecule that could be developed into an AIDS drug. Called KPC-2, it has proved capable of treating viruses in animals and can be administered by injection or taken orally.

Kucera is using a commercial lab to test KPC-2.